DalsnaFinance Account

Castle Biosciences Inc $CSTL

Health Care

Russell 2000 Texas

Create a scorecard

$33.19

-1.18 (-3.43%)

As of Oct 22, 2026, 9:33 PM EDT · cached

Price history

Loading chart…

Castle Biosciences Inc (CSTL) is trading down at $33.19 (-3.43%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: July 25, 2019 · $16.00 offering · NASDAQ · View IPO details →

Castle Biosciences Inc revenue & net income history (FY2018–FY2025)

RevenueNet incomeNet margin (right axis, %)

Castle Biosciences Inc annual financial statements
	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$22.8M	$51.9M	$62.6M	$94.1M	$137.0M	$219.8M	$332.1M	$344.2M
Growth (year over year)	—	+127.6%	+20.8%	+50.2%	+45.7%	+60.4%	+51.1%	+3.7%
Gross profit	$17.5M	$44.6M	$53.0M	$78.3M	$105.0M	$174.8M	$271.9M	$273.2M
Gross margin	76.8%	85.9%	84.5%	83.2%	76.6%	79.5%	81.9%	79.4%
Operating income	−$3.84M	$7.33M	−$6.54M	−$40.1M	−$72.9M	−$68.0M	$8.67M	−$42.8M
Operating margin	−16.8%	14.1%	−10.4%	−42.6%	−53.2%	−30.9%	2.6%	−12.4%
Net income	−$6.37M	$5.28M	−$10.3M	−$31.3M	−$67.1M	−$57.5M	$18.2M	−$24.2M
Net margin	−27.9%	10.2%	−16.4%	−33.3%	−49.0%	−26.1%	5.5%	−7.0%
EPS (diluted)	−$5.33	−$0.21	−$0.54	−$1.24	−$2.58	−$2.14	$0.62	−$0.83
Balance sheet
Cash and equivalents	$4.48M	$98.8M	$409.9M	$329.6M	$122.9M	$98.8M	$119.7M	$116.7M
Total assets	$22.4M	$119.7M	$439.3M	$462.6M	$447.3M	$453.3M	$531.2M	$578.6M
Total liabilities	$32.5M	$34.6M	$23.6M	$50.8M	$48.2M	$62.1M	$75.4M	$107.7M
Long-term debt	$24.5M	$19.3M	$0	—	—	$0	$9.74M	$9.64M
Shareholders' equity	−$56.6M	$85.1M	$415.7M	$411.7M	$399.1M	$391.3M	$455.8M	$470.9M
Cash flow
Operating cash flow	−$12.3M	$7.01M	$9.87M	−$19.0M	−$41.7M	−$5.63M	$64.9M	$64.3M
Capital expenditure	$277.0K	$937.0K	$4.75M	$3.48M	$5.63M	$13.6M	$28.3M	$36.0M
Free cash flow	−$12.6M	$6.08M	$5.11M	−$22.5M	−$47.3M	−$19.2M	$36.5M	$28.3M

RevenueNet incomeNet margin (right axis, %)

Castle Biosciences Inc quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$85.8M	$86.3M	$88.0M	$86.2M	$83.0M	$87.0M	$83.7M	$103.5M
Growth (year over year)	+39.5%	+30.5%	+20.6%	−0.9%	−3.2%	+0.8%	−4.9%	+20.1%
Gross profit	$70.2M	$70.1M	$71.6M	$68.6M	$64.3M	$68.7M	$63.1M	$79.8M
Gross margin	81.8%	81.3%	81.4%	79.5%	77.5%	79.0%	75.5%	77.1%
Operating income	$5.08M	$4.05M	−$27.9M	−$4.25M	−$6.80M	−$3.83M	−$18.4M	−$3.07M
Operating margin	5.9%	4.7%	−31.7%	−4.9%	−8.2%	−4.4%	−22.0%	−3.0%
Net income	$2.27M	$9.59M	−$25.8M	$4.52M	−$501.0K	−$2.33M	−$14.5M	−$2.06M
Net margin	2.6%	11.1%	−29.4%	5.2%	−0.6%	−2.7%	−17.4%	−2.0%
EPS (diluted)	$0.08	$0.32	−$0.90	$0.15	−$0.02	−$0.06	−$0.49	−$0.07
Balance sheet
Cash and equivalents	$95.0M	$119.7M	$89.7M	$82.2M	$85.6M	$116.7M	$63.8M	$62.1M
Total assets	$514.6M	$531.2M	$501.7M	$544.7M	$562.8M	$578.6M	$547.8M	$561.2M
Total liabilities	$73.5M	$75.4M	$61.4M	$89.4M	$95.7M	$107.7M	$86.4M	$91.1M
Long-term debt	$10.0M	$9.74M	$8.92M	$8.10M	$10.0M	$9.64M	$8.40M	$7.16M
Shareholders' equity	$441.1M	$455.8M	$440.3M	$455.4M	$467.0M	$470.9M	$461.4M	$470.0M
Cash flow
Operating cash flow	$23.3M	$24.4M	−$6.04M	$20.8M	$22.6M	$26.9M	−$22.1M	$15.2M
Capital expenditure	$6.38M	$7.57M	$4.74M	$9.26M	$14.8M	$7.18M	$12.5M	$8.65M
Free cash flow	$17.0M	$16.8M	−$10.8M	$11.6M	$7.80M	$19.7M	−$34.6M	$6.55M

From Castle Biosciences Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →